Evidence Hub

Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series

Benjamin B. Albright, S. Shuey, Angeles Alvarez Secord, L. Havrilesky, A. Berchuck, R. Previs

Gynecologic Oncology Reports, 2023

7 participants · 9 citations

Abstract

Highlights • Case series of 7 patients with heavily pretreated adult-type granulosa cell tumors of the ovary.• Included patients were treated with cyclin dependent kinase 4/6 inhibitors in combination with antiestrogen therapy.• Partial response was observed in 3 patients and stable disease confirmed in 2 patients.• At the time of data cutoff, 3 patients remained on therapy and 5 patients were alive, with medians not yet reached. The most frequent toxicity was neutropenia; toxicity led to dose reduction in 3 patients and discontinuation in 1 patient.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 7 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free